Drugs / SHR0302
Trials 38 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04146207 | Apr 2020 → Sep 2024 | chronic graft versus host disease | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT07098117 | Jun → Jul 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06202612 | Jan → Feb 2024 | autoimmune disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05900089 | May 2023 → Nov 2025 | peripheral T-cell lymphoma, not otherwise specified | Henan Cancer Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05856058 | May → Jul 2023 | graft versus host disease | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05392127 | Jul → Aug 2022 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05404724 | Jun → Jul 2022 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05047341 | Sep 2021 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04712838 | Mar → Apr 2021 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04293029 | May → Dec 2020 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02892370 | Aug → Sep 2016 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02665910 | May → Dec 2016 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02423538 | Apr 2015 → Jul 2016 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07641010 | Jun 2026 → Sep 2028 expected | Hodgkins lymphoma | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07381114 | Feb → Dec 2026 expected | acute graft versus host disease | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07634848 | Jun 2026 → May 2027 | Behcet disease | Liu Tian | Withdrawn | No outcome recorded |
| Phase 2 | NCT07505186 | May 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07570745 | May 2026 → May 2028 expected | acute graft versus host disease | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT07324473 | Jan 2026 → Jan 2028 expected | hepatocellular carcinoma | First Affiliated Hospital of Chongqing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07313202 | Dec 2025 → Dec 2027 expected | — | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07251595 | Dec 2025 → Mar 2027 expected | vitiligo | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06925048 | Apr 2025 → Dec 2026 expected | non-small cell lung carcinoma | Chunxia Su | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06731153 | Dec 2024 → Jun 2027 expected | triple-negative breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06519526 | Aug 2024 → Feb 2027 expected | peripheral T-cell lymphoma, not otherwise specified | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT03677648 | May 2019 → Sep 2021 | Crohn disease | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT03675477 | Apr 2019 → Nov 2020 | ulcerative colitis | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT03254966 | Nov 2017 → Apr 2019 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04481139 | Oct 2020 → Nov 2022 | ankylosing spondylitis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT05324631 | Aug 2022 → Aug 2024 | spondyloarthropathy | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05181137 | Nov 2021 → Oct 2024 | ulcerative colitis | Reistone Biopharma Company Limited | Unknown | No outcome recorded |
| Phase 3 | NCT04957550 | Aug 2021 → Nov 2024 | psoriatic arthritis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04875169 | Apr 2021 → Aug 2022 | atopic eczema | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT04333771 | Jul 2020 → Jan 2023 | rheumatoid arthritis | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07451665 | Apr 2026 → Mar 2029 expected | Takayasu arteritis | Chinese SLE Treatment And Research Group | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07452445 | Mar 2026 → Mar 2028 expected | rheumatoid arthritis | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT07550452 | Mar 2026 → Jun 2027 expected | atopic eczema | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07276620 | Nov 2025 → Apr 2028 expected | atopic eczema | Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| — | NCT07270003 | Oct 2025 → Oct 2026 expected | palmoplantar pustulosis | Xijing Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 6 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04346316 Comparator | May 2020 → Jun 2021 | alopecia areata | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Phase 2 | NCT04162899 Comparator | Nov 2019 → Aug 2020 | atopic eczema | Reistone Biopharma Company Limited | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04717310 Comparator | Dec 2020 → Sep 2023 | atopic eczema | Reistone Biopharma Company Limited | Unknown | No outcome recorded |
| Phase 2/3 | NCT04774809 Comparator | Jan 2020 → Mar 2022 | vitiligo | Reistone Biopharma Company Limited | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05470413 Comparator | Apr 2022 → Oct 2023 | alopecia areata | Reistone Biopharma Company Limited | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07266168 Comparator | Jan 2026 → Dec 2027 expected | polymyalgia rheumatica | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 46 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR0302 | “Ivarmacitinib (SHR0302) is a highly selective oral JAK1 inhibitor” NCT07570745 ↗30 |
| Known as | Ivarmacitinib | “A Prospective, Multicenter, Randomized Controlled Clinical Study of Camrelizumab in Combination With Ivarmacitinib as First-line Treatment for Pediatric Classical Hodgkin Lymphoma” NCT07641010 ↗14“Ivarmacitinib (SHR0302), a selective Janus kinase 1 inhibitor” PMID 41357869 ↗ Nov 2025 |
| Action | Inhibit | “SHR0302 is a Janus kinase 1(JAK1) inhibitor, capable of blocking Janus kinase-signal transducer and activator of transcription (JAK-STATs) pathway and controlling inflammation.” NCT03675477 ↗ |
| Modality | Small molecule | “Ivarmacitinib is a novel small-molecule targeted drug” NCT07452445 ↗ |
| Route | Oral | “single ascending (SAD) oral doses of SHR0302” NCT02423538 ↗ |
| Target | JAK1 | “A Novel JAK1 Inhibitor SHR0302 Combined With Prednisone for First-Line Treatment of Chronic Graft-versus-Host Disease: A Phase I Clinical Trial.” PMID 38798038 ↗ Jan 2024 |